SecBot SecBot

GNTA

Genenta Science S.p.A.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. L6· CIK 0001838716 Biotech & Drug Discovery
$0.6182 −0.01 (−0.93%)
Oct 27 4:00 PM ET · prev $0.6240
Market cap
$30.4M
Nano cap
Median target
$6.98
+1030% · range $6.98–6.98
1 year
−74.2%
from $2.40 · Oct 28
30 days
−10.4%
from $0.6900
52-week range
$0.5800–3.01
−79% from high · low May 22
Avg volume 20D
44.3K
Oct 19 spike 129.0K
Short interest
108.1K
≈0.2% of shares · −1.8%
Days to cover
2.1
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q1 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 3 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/6
Strongest BEARISH Genenta Science received a Nasdaq deficiency notice for failing to maintain a minimum $1.00 bid price for 30…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q1 2026: 0 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest −1.8% to 108.1K shares. 2.1 days to cover, ≈0.2% of shares.

  • TrendDOWNTREND

    25% below its 50-day average.

Who's buying

13F· Q1 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYTRIM15,420$10.4K
MORGAN STANLEYDOUBLED45,900$68.4K
ALLIANZ SEDOUBLED233,550$927.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Oct 2024
12-month targets · 1 analysts

Price is below the lowest target. Median implies +1030%.Targets as of Apr 27, 2026.

Recent actions
DateFirmActionRating
Oct 2, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
May 13, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Feb 8, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
Jan 5, 2023EF Hutton
INITIATE
INITIATEBuy
Jul 25, 2022HC Wainwright & Co.
INITIATE
INITIATEBuy
Jan 13, 2022Maxim Group
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Mar 30, 2026
SLANSKY RICHARD B
Chief Financial Officer
AWARD80,000 sh
Mar 30, 2026
Sharei Armon
Director
AWARD20,000 sh
Mar 30, 2026
Galimi Francesco
CMO& Head of Development
AWARD20,000 sh
Mar 30, 2026
Mutti Miguel Maria
Director
AWARD20,000 sh
Mar 30, 2026
PARACCHI GIACOMOANTONIO
Director
AWARD20,000 sh
Mar 30, 2026
Paracchi Pierluigi
Chief Executive Officer
AWARD100,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
108,069
shares short
-1.8%
vs prior settlement
2.1
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 24, 2026 Listing status
Listing Status: GNTA — Deficient (was Normal)
Genenta Science S.p.A. - American Depositary Shares | Nasdaq Financial Status Indicator N → D
Oct 22, 2026 SEC
The Tribunal of Milan issued an interim order suspending the June 29, 2026 shareholder resolution that appointed a new…
6-K — Impact 4/10
Oct 21, 2026 SEC
Genenta Science received a Nasdaq minimum bid price deficiency notice on October 16, 2026, as its ADSs closed below…
6-K — Impact 6/10
Oct 21, 2026 Press
Genenta Science received a Nasdaq deficiency notice for failing to maintain a minimum $1.00 bid price for 30…
Impact 7/10
Oct 13, 2026 SEC
Genenta Science S.p.A. reported that its Extraordinary Shareholders' Meeting failed to approve a proposed name change…
6-K — Impact 5/10
Mar 31, 2026 Inst.
MORGAN STANLEY — TRIM
15,420 shares ($10.4K)
Mar 30, 2026 Insider
SLANSKY RICHARD B was granted 80,000 shares
Chief Financial Officer
Mar 30, 2026 Insider
Sharei Armon was granted 20,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 24, 2026
Listing
Listing Status: GNTA — Deficient (was Normal)
Genenta Science S.p.A. - American Depositary Shares | Nasdaq Financial Status Indicator N → D
Oct 21, 2026
Activist
Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification
MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that on October 16, 2026, it...
Sep 15, 2026
Press release
Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit
Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit.
Jul 23, 2026
Press release
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
Jul 22, 2026
Earnings
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
Sòphia High Tech S.r.l. is an Italian aerospace and defense engineering and manufacturing company. Financial Statements FY25

SecBot reports

12 filings · 3 press releases · 2 bullish · 3 bearish · 1 mixed · 6 neutral
All GNTA filing & press-release reports (15)